Alirocumab (Praluent®)

Assessment Status NCPE Assessment Process Complete
Drug Alirocumab
Brand Praluent®
Indication For the treatment of both primary hypercholesterolaemia (heterozygous familial and non-familial) or mixed dyslipidaemia
Assessment Process
Rapid review commissioned 13/10/2015
Rapid review completed 02/11/2015
Rapid review outcome Full Pharmacoeconomic Evaluation Recommended
Full submission received from Applicant 04/01/2016
NCPE assessment completed 06/06/2017
NCPE assessment outcome Following NCPE assessment of the company submission, alirocumab (Praluent®) is not considered cost effective for the treatment of primary hypercholesterolemia and mixed dyslipidemia and is therefore not recommended for reimbursement.


The HSE has re-commissioned a full HTA for this product as of 20th March 2018
Full pharmacoeconomic assessment re-commissioned by HSE 20/03/2018
Pre-submission consultation with Applicant 08/10/2018
Submission received from Applicant 27/02/2019

Technical Summary

The HSE has approved reimbursement following confidential price negotiations, April 2021.